Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 250 of 496 entries
View as:

A Study of rhuMAb VEGF (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Treated Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00109239 Org: User:
Start: 11/30/00 End: 09/30/02 Due: 09/30/03

A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)

Phase: N/A Priority: Normal
NCT ID: NCT01087151 Org: User:
Start: 08/31/10 End: 06/30/12 Due: 06/30/13

Safety and Tolerability of Pirfenidone in Participants With Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) (LOTUSS)

Phase: N/A Priority: Normal
NCT ID: NCT01933334 Org: User:
Start: 10/31/13 End: 09/30/14 Due: 09/30/15

A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN)

Phase: N/A Priority: Normal
NCT ID: NCT00345163 Org: User:
Start: 07/31/06 End: 09/30/07 Due: 09/30/08

A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Phase: N/A Priority: Normal
NCT ID: NCT01671904 Org: User:
Start: 01/13/14 End: 08/11/20 Due: 08/11/21

Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing

Phase: N/A Priority: Normal
NCT ID: NCT00813748 Org: User:
Start: 03/31/09 End: 01/31/14 Due: 01/31/15

A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Single and Multiple Ascending Doses of GDC-0334 and the Effect of Food on the Pharmacokinetics of GDC-0334 in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT03381144 Org: User:
Start: 12/08/17 End: 04/29/19 Due: 04/29/20

A Study of MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS

Phase: N/A Priority: Normal
NCT ID: NCT01986166 Org: User:
Start: 11/30/13 End: 01/31/16 Due: 01/31/17

Safety Study of rhuMAb 2C4 to Treat Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00027027 Org: User:
Start: 11/30/01 End: 08/31/03 Due: 08/31/04

A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus

Phase: N/A Priority: Normal
NCT ID: NCT00381810 Org: User:
Start: 06/22/06 End: 02/29/12 Due: 02/28/13

A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01122875 Org: User:
Start: 11/30/10 End: 05/31/12 Due: 05/31/13

A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g)

Phase: N/A Priority: Normal
NCT ID: NCT00517049 Org: User:
Start: 03/31/08 End: 12/31/09 Due: 12/31/10

A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03916744 Org: User:
Start: 07/26/19 End: 05/25/21 Due: 05/25/22

A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)

Phase: N/A Priority: Normal
NCT ID: NCT02273973 Org: User:
Start: 11/12/14 End: 03/13/17 Due: 03/13/18

A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment

Phase: N/A Priority: Normal
NCT ID: NCT01287117 Org: User:
Start: 02/28/11 End: 10/31/12 Due: 10/31/13

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT04910568 Org: User:
Start: 07/26/21 End: 12/10/25 Due: 12/10/26

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-9545 Following a Single Oral Dose (Part 1) and to Evaluate the Absolute and Relative Bioavailability of Oral Capsule Formulations of GDC-9545 (Part 2) in Healthy Female Subjects of Non-Childbearing Potential

Phase: N/A Priority: Normal
NCT ID: NCT04680273 Org: User:
Start: 01/07/21 End: 04/12/21 Due: 04/12/22

A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01296555 Org: User:
Start: 03/16/11 End: 06/25/21 Due: 06/25/22

A Study of Pulmozyme® (Dornase Alpha) in 3- to 5-Year-Old Patients With Cystic Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT00680316 Org: User:
Start: 06/30/08 End: 05/31/09 Due: 05/31/10

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of BFKB8488A in Otherwise Healthy Overweight and Obese Participants With Likely Insulin Resistance

Phase: N/A Priority: Normal
NCT ID: NCT02593331 Org: User:
Start: 10/29/15 End: 03/28/17 Due: 03/28/18

Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab

Phase: N/A Priority: Normal
NCT ID: NCT04377555 Org: User:
Start: 07/30/20 End: 12/29/25 Due: 12/29/26

A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03289962 Org: User:
Start: 12/21/17 End: 06/30/25 Due: 06/30/26

A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00452127 Org: User:
Start: 05/31/07 End: - Due: -

The Mycophenolate Pregnancy Registry

Phase: N/A Priority: Normal
NCT ID: NCT01733082 Org: User:
Start: 11/20/12 End: 08/29/25 Due: 08/29/26

Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC)

Phase: N/A Priority: Normal
NCT ID: NCT01652482 Org: User:
Start: 10/31/12 End: 11/30/14 Due: 11/30/15